Gilgamesh Pharmaceuticals
PrivateLast Round
Series A
Mar 24, 2026
Est. Valuation
$100M
Total Funding Raised
$212.08M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Gilgamesh Pharmaceuticals is a biotechnology company that develops innovative new chemical entities for the treatment of neurological and psychiatric disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gilgamesh Pharmaceuticals Comparables
Compare Gilgamesh Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Definium Therapeutics | 84% | |
| Enveric Biosciences, Inc. | 83% | |
| Otsuka Holdings | 82% |
Gilgamesh Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 | ||||
| Corporate Funding | May 13, 2024 | ||||
| Grant | Mar 14, 2024 | ||||
| Series B | Dec 15, 2022 | ||||
| Series A | May 6, 2021 | ||||
Accelerator | Aug 24, 2020 |
Gilgamesh Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Negev Capital | Series B |
| Noetic Fund | Series A |
| Route 66 Ventures | Series A, Series B |
| Gron Ventures | Series A, Series B |
| Y Combinator | Accelerator, Seed |
| Prime Movers Lab | Series A, Series B |
| Satori Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
GM-3009, a novel ibogaine derivative for PTSD, is in early-stage clinical testing.
- Mar 24, 2026
$60M round completed.
Recent news
Latest coverage and updates
- sells_assets_toAug 19, 2026
Gilgamesh Pharma Inc. sells assets to AbbVie in the amount of $1.2B.
- is_developingJul 14, 2026
Gilgamesh Pharmaceutical is developing cardiac-safe analog of ibogaine for substance use disorders on Jul 14th '26.
Gilgamesh Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Gilgamesh Pharmaceuticals's valuation, stock price, and market status.
Is Gilgamesh Pharmaceuticals a public or private company?
Gilgamesh Pharmaceuticals is a private company.
What is the current stock price of Gilgamesh Pharmaceuticals?
Gilgamesh Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Gilgamesh Pharmaceuticals worth (valuation)?
Gilgamesh Pharmaceuticals's valuation is estimated at $1.8M based on funding round data.
Can I buy Gilgamesh Pharmaceuticals stock?
Gilgamesh Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Gilgamesh Pharmaceuticals's last funding round?
Gilgamesh Pharmaceuticals's most recent funding round was Series A on August 24, 2020.
Who are the main investors in Gilgamesh Pharmaceuticals?
Key investors in Gilgamesh Pharmaceuticals include Prime Movers Lab, Satori Neuro.
Will Gilgamesh Pharmaceuticals IPO soon?
No public IPO plans have been announced for Gilgamesh Pharmaceuticals.
How can I track Gilgamesh Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Gilgamesh Pharmaceuticals's secondary market activity and sign up for updates.